LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

Home・Stock List・Coherus Biosciences Inc

Coherus Biosciences Inc

Closed

Sector Healthcare

1.24 -5.34

Buy Sell

Overview

Share price change

24h

Current

Min

1.24

Max

1.25

Key metrics
By Trading Economics
Sales	17M 92M
EPS	-0.62
Employees	306

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+440.15 upside

Dividends
By Dow Jones
Next Earnings	4 Nov 2024

Market Stats
By TradingEconomics
Market Cap	4.5M 278M
Previous open	6.58
Previous close	1.24

News Sentiment

By Acuity

50%

114 / 365 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

N/A / 1.39 Support & Resistance

Coherus Biosciences Inc Chart

Related News

22 Jan 2024, 06:44 UTC

Acquisitions, Mergers, Takeovers

Sandoz to Acquire Cimerli Business from Coherus for $170 Million

27 Oct 2023, 21:40 UTC

Major Market Movers

Coherus BioSciences Shares Climb 12% on FDA Approval for Cancer Treatment Loqtorzi

22 Jan 2024, 06:29 UTC

Acquisitions, Mergers, Takeovers

Sandoz to Acquire Cimerli Business from Coherus for $170M

Peer Comparison

Price change

Coherus Biosciences Inc Forecast

Price Target

By TipRanks

440.15% upside

12 Months Forecast

Average 7.13 USD 440.15%

High 12 USD

Low 1.5 USD

Based on 6 Wall Street analysts offering 12 month price targets forCoherus Biosciences Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

6 ratings

Buy

Hold

Sell

Based on 6 analysts giving stock ratings to Coherus Biosciences Inc - Dist in the past 3 months.

Technical Score

By Trading Central

N/A / 1.39Support & Resistance

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

There are no events.

Sentiment

By Acuity

114 / 365 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Coherus Biosciences Inc

Coherus BioSciences, Inc. is a commercial stage biotherapeutics company. The Company is focused on the biosimilar and immuno-oncology market primarily in the United States. The Company’s pipeline includes the four categories product candidates, Oncology pipeline, Immunology pipeline, Ophthalmology pipeline and Small Molecule pipeline. Oncology pipeline includes Toripalimab, an anti-PD-1 antibody; UDENYCA (pegfilgrastim-cbqv); CHS-305, a bevacizumab (Avastin) biosimilar. Immunology pipeline includes CHS-1420, an anti-TNF product candidate, as an adalimumab (Humira) biosimilar. Ophthalmology pipeline includes CHS-201, a ranibizumab (Lucentis) biosimilar. CHS-201, a ranibizumab (Lucentis) biosimilar. Small Molecule pipeline includes CHS-131, an oral, small-molecule drug candidate. CHS-131 is a once-daily oral drug candidate for non-alcoholic steatohepatitis (NASH) and other metabolic conditions.